Skip to main content
Figure 3 | Molecular Pain

Figure 3

From: Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery

Figure 3

Neither the CB 1 antagonist AM251 nor the CB 2 antagonist AM630 altered paclitaxel-induced mechanical or cold allodynia. a. No changes in body weight, responsiveness to b. mechanical, or c. cold stimulation were observed in paclitaxel-treated animals receiving AM630 (3 mg/kg/day s.c.) or AM251 (3 mg/kg/day s.c.) relative to Taxol-vehicle animals. *P < 0.05, **P < 0.01, ***P <0.001 vs. Cremophor-Vehicle, ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 Taxol-AM630 (3 mg/kg/day s.c.) and Taxol-AM251 (3 mg/kg/day s.c.) vs. Cremophor-Vehicle, # P < 0.05 vs. Taxol-Vehicle, ϕ P < 0.05 Taxol-AM630 (3 mg/kg/day s.c.) and Taxol-AM251 (3 mg/kg/day s.c.) vs. Taxol-Vehicle and Cremophor-Vehicle. Doses are in mg/kg/day s.c. (ANOVA; Dunnett and Tukey post-hoc tests). N = 10–18 per group.

Back to article page